Naegis Pharmaceuticals Inc.

Naegis Pharmaceuticals is developing treatments for inflammatory conditions with a focus on the discovery and development of novel small molecules that target pro-inflammatory mediators involved in ocular and pulmonary diseases. The company’s most advanced program is a lead compound that reaches the back of the eye upon topical (eye drop) administration, thereby opening up the potential to treat diseases of the retina without the need to administer the therapy systemically or surgically.